Obinutuzumab

證據等級: L5

預測適應症: 3 個

Obinutuzumab: From CD20+ B-Cell Malignancies (Not Yet Marketed in Taiwan) to Follicular Lymphoma

One-Sentence Summary

Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody with no marketing authorization currently on file in Taiwan (0 licenses). The TxGNN model’s strongest-evidence signal points to Follicular Lymphoma, a globally established anti-CD20 antibody indication, with 46 clinical trials and 20 publications in this evidence pack — including two completed Phase 3 RCTs (GALLIUM, GADOLIN) — supporting the mechanism. Two additional model outputs (pregerminal-center CLL/SLL and IGHV-hypermutated CLL/SLL) scored equally high but returned zero matched trials or literature, likely reflecting disease-label granularity rather than a new signal — see note below.

Quick Overview

Item	Content
Original Indication	Not currently marketed in Taiwan; drug class is targeted at CD20+ B-cell malignancies (chronic lymphocytic leukemia/small lymphocytic lymphoma) per the model’s own rationale text
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.18% (rank 3 candidate; see note on two higher-listed but evidence-free candidates below)
Evidence Level	L1
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Note on the top-ranked candidates: The two highest-ranked predictions (score ≈99.2%) — “pregerminal center CLL/SLL” and “CLL/SLL with IGHV somatic hypermutation” — returned no matched clinical trials or literature in this evidence pack. The model’s own rationale flags this as a probable disease-term matching artifact: these are molecular subtypes of CLL/SLL, not distinct disease entities, and CLL/SLL as a whole already has a large body of approved-drug evidence (e.g., CLL14, iLLUMINATE) that simply isn’t indexed under these precise subtype labels. They are classified L4/”Research Question” and are not decision-ready. This report therefore focuses on the third-ranked, evidence-rich candidate — Follicular Lymphoma — which is the only one of the three reaching a Guardrails-level recommendation.

Why is This Prediction Reasonable?

Formal DrugBank mechanism-of-action data is flagged as a gap in this evidence pack (DG002). Based on the information available in the model’s rationale, however, obinutuzumab is a type II, glycoengineered, humanized anti-CD20 IgG1 monoclonal antibody. Compared with first-generation anti-CD20 agents such as rituximab, it produces stronger antibody-dependent cellular cytotoxicity (ADCC) and greater direct/non-apoptotic cell death, while inducing less complement-dependent cytotoxicity.

CD20 is expressed on malignant B-cells across the indolent and aggressive non-Hodgkin lymphoma spectrum, including both CLL/SLL and follicular lymphoma. The mechanistic rationale is therefore not a stretch: obinutuzumab already carries international marketing approval for follicular lymphoma (approved by FDA in 2016 as Gazyva, based on the GALLIUM and GADOLIN trials), so this “prediction” is best understood as the model correctly re-identifying an already-validated pharmacological pathway rather than proposing a novel hypothesis. Its practical relevance for this evidence pack is that Taiwan currently has zero marketing authorizations on file for this drug — so the decision in front of stakeholders is a market-entry/registration question, not a scientific-plausibility question.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06191744	Phase 3	Recruiting	1095	Epcoritamab + rituximab/lenalidomide vs. chemoimmunotherapy in previously untreated FL
NCT02871219	Phase 2	Completed	96	Obinutuzumab + lenalidomide in previously untreated FL
NCT01582776	Phase 1/2	Completed	317	Obinutuzumab + lenalidomide across untreated and R/R FL cohorts
NCT03332017	Phase 2	Completed	217	Zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in R/R FL
NCT03817853	Phase 4	Completed	114	Post-marketing study of obinutuzumab short-duration infusion in untreated advanced FL
NCT03492775	Phase 2	Completed	46	Obinutuzumab monotherapy vs. obinutuzumab + bendamustine in compromised/elderly patients
NCT05929222	Phase 3	Recruiting	190	GAZEBO trial: radiotherapy alone vs. + obinutuzumab in early-stage FL
NCT04450173	Phase 2	Active, not recruiting	40	Obinutuzumab + ibrutinib + venetoclax in untreated FL
NCT06108232	Phase 2	Active, not recruiting	33	Obinutuzumab + CC-99282 in high tumor burden, untreated FL
NCT05899621	N/A	Recruiting	332	Real-world efficacy/safety of obinutuzumab-based therapy in untreated FL

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28976863	2017	RCT	N Engl J Med	GALLIUM primary analysis: obinutuzumab-chemo vs. rituximab-chemo in untreated advanced FL
29856692	2018	RCT	J Clin Oncol	GALLIUM: influence of chemotherapy backbone on obinutuzumab efficacy/safety
37506346	2023	RCT	J Clin Oncol	ROSEWOOD: zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in R/R FL
37404773	2023	RCT	HemaSphere	GALLIUM final analysis: obinutuzumab- vs. rituximab-based immunochemotherapy in untreated iNHL
31296423	2019	RCT	Lancet Haematol	GALEN: obinutuzumab + lenalidomide in R/R follicular B-cell lymphoma
28324270	2017	Review	Targeted Oncol	Review incl. pivotal GADOLIN Phase 3 data (obinutuzumab + bendamustine in rituximab-refractory FL)
37767550	2024	Cohort	Haematologica	Phase Ib/II: polatuzumab vedotin + bendamustine/obinutuzumab or rituximab in R/R FL
31360086	2017	Review	Blood Lymphat Cancer	Overview of obinutuzumab alone and in combination for FL
38660754	2024	Review	Turk J Haematol	Comprehensive review of FL management incl. anti-CD20 antibody options
39830356	2024	Review	Front Pharmacol	Rapid review of efficacy, safety, and cost-effectiveness of obinutuzumab in FL

Taiwan Market Information

No marketing authorizations are on file. taiwan_regulatory.total_licenses = 0 and the licenses array is empty — obinutuzumab currently has no registered product in this jurisdiction.

Cytotoxicity

Obinutuzumab is an antineoplastic agent (indicated for B-cell lymphoid malignancies); this section is included per that classification.

Item	Content
Cytotoxicity Classification	Targeted immunotherapy — type II, glycoengineered anti-CD20 monoclonal antibody (not conventional cytotoxic chemotherapy)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all flagged as gaps in this evidence pack; TFDA label retrieval is listed as a blocking data gap — DG001.)

Conclusion and Next Steps

Decision: Proceed with Guardrails (for Follicular Lymphoma)

Rationale:

Two completed Phase 3 RCTs (GALLIUM, GADOLIN) plus 46 supporting trials and 20 publications establish obinutuzumab’s efficacy in FL as an internationally validated, not merely hypothetical, indication — this is an L1-level evidence base.
The drug has zero Taiwan marketing authorizations, so the practical decision is one of local registration/market entry rather than novel mechanism validation.
The two higher-scoring CLL/SLL subtype predictions remain at “Research Question” (L4/S1) status and should not be advanced without first cross-checking against the existing CLL/SLL evidence base under standard (non-subtype) disease terms.

To proceed, the following is needed:

TFDA label/warnings and contraindications data (DG001 — currently blocking full safety review)
Formal DrugBank MOA record (DG002)
Confirmation of Taiwan NDA/registration pathway status for obinutuzumab
Re-run evidence retrieval for CLL/SLL under standard disease terminology to resolve the rank 1/2 label-matching gap before treating them as independent candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.